Characterization of Proteomic Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics to Inform Potential Utility in Biosimilar Development
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3754 ↗At a glance
Randomisierte kontrollierte Studie in Clinical Pharmacology & Therapeutics, 2025. Written by Lakshmi Manasa S Chekka and 15 co-authors. Institution: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U…. Major MEDLINE topics: Biosimilar Pharmaceuticals, Proteomics, Interferon beta-1a, Interferon-beta. Cited 3 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Pharmacodynamic (PD) biomarkers can support biosimilarity assessment, potentially reducing the need for comparative clinical efficacy studies. This study aimed to characterize previously identified proteomic PD biomarker candidates for Interferon beta‐1a (IFNβ‐1a, n = 248) and pegylated IFNβ‐1a (pegIFNβ‐1a, n = 528) biologics at therapeutic doses, to further evaluate the utility of proteomics in biosimilar development. Here, we reproduced the results at lower doses and characterized PD responses across multiple doses using criteria for justifying PD biomarker use in biosimilar development. We analyzed candidate proteins from longitudinal proteomics data (SomaScan™ Assay v4.1) from 48 healthy subjects administered intermediate or low doses of IFNβ‐1a (15, 7.5 μg) or pegIFNβ‐1a (62.5, 31.25 μg) in an FDA‐sponsored study, alongside previously published therapeutic dose and placebo data. EDTA plasma samples were collected at 0, 0.125, 0.33, 0.67, 1.33, 2, 3, 4, 5, 6 days and at 9, 13 days additionally for pegIFNβ‐1a. Prioritization criteria included significant differential expression at the intermediate dose vs. placebo, ≥20% response difference from placebo, significant baseline‐adjusted area under the effect curve (AUEC) and a monotonic dose–response relationship across all doses. Among the candidates, 165 and 323 were differentially expressed at intermediate doses of IFNβ‐1a and pegIFNβ‐1a respectively. Nine PD biomarkers, including C‐X‐C motif chemokine 11 (I‐TAC), Lymphocyte activation gene 3 protein (LAG3), and Granulins (GRN), were prioritized as common to both biologics. Most candidates followed the E max dose–response model. I‐TAC showed the strongest response, and LAG‐3 showed the least variability in AUEC. Our study identified several suitable plasma PD biomarkers for IFNβ‐1a and pegIFNβ‐1a biologics with potential utility in biosimilar development programs.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
- Therapeutic Biologics Program, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
- Information Management Services, Inc, Rockville, Maryland, USA.
- Spaulding Clinical Research, West Bend, Wisconsin, USA.
- Standard BioTools, Inc, Boulder, Colorado, USA.
- Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
ORCID profiles: Lakshmi Manasa S Chekka, Deepti P Samarth, Erica Decker, Qin Sun, Joseph Gogain, Yow-Ming Wang, David G Strauss
Cite
APA
Chekka, L. M. S., Samarth, D. P., Guo, Y., Mohamed, E. G., Decker, E., Matta, M. K., Sun, Q., Wheeler, W., Sanabria, C., Wommack, J., Gogain, J., Schrieber, S. J., Florian, J., Wang, Y. M., Strauss, D. G., & Hyland, P. L. (2025). Characterization of Proteomic Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics to Inform Potential Utility in Biosimilar Development. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3754
Vancouver
Chekka LMS, Samarth DP, Guo Y, Mohamed EG, Decker E, Matta MK, et al. Characterization of Proteomic Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics to Inform Potential Utility in Biosimilar Development. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3754
BibTeX
@article{Chekka2025,
author = {Chekka, Lakshmi Manasa S and Samarth, Deepti P and Guo, Yan and Mohamed, Esraa G and Decker, Erica and Matta, Murali K and Sun, Qin and Wheeler, William and Sanabria, Carlos and Wommack, Joel and Gogain, Joseph and Schrieber, Sarah J and Florian, Jeffry and Wang, Yow-Ming and Strauss, David G and Hyland, Paula L},
title = {Characterization of Proteomic Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics to Inform Potential Utility in Biosimilar Development},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3754}
}
EUVIMED